Currently, it is crucial and required that molecular testing has to be performed before the personalized treatment with ALK inhibitors can be initiated, thus approx. 10%–50% of all NSCLC patients must receive ALK testing during their course of disease, resulting in 35,000 to 175,000 tests per year in Europe. The gene discussed is ALK; the disease is non-small cell lung carcinoma.